Publication at Faculty of Medicine in Hradec Králové |
2016
Abstract
Alirocumab (Praluent) belong to a new, very promising and extremely effective lipid lowering drugs, with the potential to significantly reduce the particularly low-density lipoprotein (LDL) cholesterol, but also other atherogenic lipids, including lipoprotein.